A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

NCT00291902 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Heart Disease

Interventions

DRUG: SB-681323

Sponsor

GlaxoSmithKline